Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Sangamo Therapeutics)"
Count: 29
Selected: 0
| NCT ID | Title |
|---|
| NCT05987527 | Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term) | ||
| NCT05145062 | Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400. | ||
| NCT05039866 | Long-Term Follow-up of Subjects Who Were Treated With ST-920 | ||
| NCT04817774 | Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients | ||
| NCT04628871 | Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX | ||
| NCT04201782 | Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T | ||
| NCT04046224 | Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR) | ||
| NCT03653247 | A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease | ||
| NCT03432364 | A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) | ||
| NCT03041324 | Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II | ||
| NCT02702115 | Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I | ||
| NCT02695160 | Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B | ||
| NCT02225665 | Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART | ||
| NCT01543152 | Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T | ||
| NCT01252641 | Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects | ||
| NCT01079325 | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy | ||
| NCT01044654 | Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients | ||
| NCT00985517 | Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease | ||
| NCT00876863 | Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease | ||
| NCT00748501 | Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | ||
| NCT00665145 | Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509 | ||
| NCT00476931 | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy | ||
| NCT00406458 | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy | ||
| NCT00400634 | Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease | ||
| NCT00252850 | Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease | ||
| NCT00110500 | Clinical Trial of SB-509-0401 in Subjects With Diabetic Neuropathy | ||
| NCT00087789 | CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease | ||
| NCT00842634 | Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV | ||
| NCT02500849 | Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients |
